Sounds like the next hurdle is getting "the nod" from Halifax’s QE II Health Sciences Centre ethics committee. 

"In the 16-week clinical trials expected to start later this year — if the research method is given the nod by the QE II’s ethics committee — the researchers led by West and Khan will measure the effects of the drug apabetalone on 44 patients suffering with Fabry disease. Half of these will be patients already on an enzyme replacement therapy to help their bodies break down those fatty substances. The reason for the two locations is to make it easier to recruit Fabry disease sufferers. There are only 440 of them in Canada.....The clinical trial is being undertaken for Calgary-based pharmaceutical company Resverlogix Corp., which got the green light in May from Health Canada’s therapeutic products directorate to go ahead."